皮炎外瓶霉临床和环境分离株对6种常用抗真菌药物的敏感性测定

中华皮肤科杂志 ›› 2010, Vol. 43 ›› Issue (10): 717-720.

皮炎外瓶霉临床和环境分离株对6种常用抗真菌药物的敏感性测定

孙毅¹,刘伟²,万喆²,陈伟³,李若瑜²

1. 北京大学第一医院
2. 北京大学第一医院皮肤科
3.

收稿日期:2010-02-26 修回日期:2010-05-11 出版日期:2010-10-15 发布日期:2010-10-09
通讯作者: 刘伟 E-mail:liuw90@yahoo.com
基金资助:
国家自然科学基金;北京市自然科学基金

In vitro susceptibility testing of 16 strains of Exophiala dermatitidis to 6 commonly used antifungal agents

Received:2010-02-26 Revised:2010-05-11 Online:2010-10-15 Published:2010-10-09

摘要/Abstract

摘要：

目的探讨临床分离的皮炎外瓶霉对6种常用抗真菌药物的敏感性。方法参考美国临床实验室标准化研究所M27-A2方案测定特比萘芬（TRB）、伊曲康唑（ITC）、两性霉素B（AMB）、氟康唑（FLC）、伏立康唑（VRC）及卡泊芬净（CAS）对16株皮炎外瓶霉的最低抑菌浓度（MIC），同时以E-test法测定VRC、ITC和AMB对16株皮炎外瓶霉的MIC，并进一步测定每种药物的最低杀菌浓度（MFC）。在此基础上，观察TRB与ITC及VRC联合应用时对皮炎外瓶霉的抗菌作用。结果微量液基稀释法测得TRB、VRC、ITC、AMB、FLC和CAS 对皮炎外瓶霉MIC范围分别为：0.125 ~ 0.25、0.25 ~ 0.5、2.0、2.0、16 ~ 32和16 ~ 64mg/L；TRB、VRC、ITC、AMB和FLC的MFC范围分别为：0.125 ~ 0.5、0.25 ~ 0.5、2.0 ~ 4.0、2.0 ~ 4.0和16 ~ 64 mg/L。E-test法测定VRC、ITC和AMB的MIC范围为：0.032 ~ 0.094、0.047 ~ 0.5和0.125 ~ 3.0 mg/L。TRB与ITC及VRC在体外联合应用对皮炎外瓶霉无协同效应。结论皮炎外瓶霉在体外对TRB、ITC、AMB、VRC敏感，对FLC和CAS不敏感。

关键词: 皮炎外瓶霉, 抗真菌药物, 体外敏感性试验

Abstract:

Objective To investigate the in vitro susceptibility of 16 strains of Exophiala dermatitidis to 6 commonly used antifungal agents. Methods The Clinical and Laboratory Standards Institute （CLSI） M27-A2 protocol was carried out to determine the MICs of terbinafine （TRB）, itraconazole （ITC）, amphotericin B （AMB）, fluconazole （FLC）, voriconazole （VRC）, and caspofungin （CAS） to 16 strains of E. dermatitidis, and E-test was performed to determine those of VRC, ITC and AMB. Besides, the minimal fungicidal concentrations （MFCs） of the above antifungal agents to the 16 strains of E. dermatitidis were further assessed. The activity of TRB in combination with ITC and VRC against E. dermatitidis was also estimated. Results The MIC ranges of TRB, VRC, ITC, AMB, FLC, and CAS were 0.125 - 0.25 mg/L, 0.25 - 0.5 mg/L, 2.0 mg/L, 2.0 mg/L, 16 - 32 mg/L and 16 - 64 mg/L respectively as shown by M27-A2 microdilution assay, while the MIC ranges of VRC, ITC and AMB, as determined by E-test, were 0.032 - 0.094 mg/L, 0.047 - 0.5 mg/L and 0.125 - 3.0 mg/L, respectively. The MFC ranges of TRB, VRC, ITC, AMB and FLC were 0.125 - 0.5 mg/L, 0.25 - 0.5 mg/L, 2.0 - 4.0 mg/L, 2.0 - 4.0 mg/L and 16 - 64 mg/L, respectively. No synergism in the acitivity against E. dermatitidis was observed for the combination of TBR with ITC or VRC. Conclusion E. dermatitidis is susceptible to TRB, ITC, AMB, and VRC, but less sensitive to both FLC and CAS.

Key words: Exophiala dermatitidis, Antifungal drugs, In vitro susceptibility test

孙毅刘伟万喆陈伟李若瑜. 皮炎外瓶霉临床和环境分离株对6种常用抗真菌药物的敏感性测定[J]. 中华皮肤科杂志, 2010, 43(10): 717-720.

参考文献

参考文献 [1] Ajello L, Georg L K, Steigbigel R T, et al. A case of phaeohyphomycosis caused by a new species of Phialophora.[J]. Mycologia,1974,66(3):490-498. [2] Revankar S G. Therapy of infections caused by dematiaceous fungi.[J]. Expert Rev Anti Infect Ther,2005,3(4):601-612. [3] Laniado-Laborin R, Cabrales-Vargas M N. Amphotericin B: side effects and toxicity.[J]. Rev Iberoam Micol,2009, 26(4):223-227. [4] Denning D W. Echinocandin antifungal drugs.[J]. Lancet,2003,362(9390):1142-1151. [5] Li D M, de Hoog G S. Cerebral phaeohyphomycosis--a cure at what lengths?[J]. Lancet Infect Dis,2009,9(6):376-383. [6] Revankar S G, Patterson J E, Sutton D A, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis.[J]. Clin Infect Dis,2002,34(4):467-476. [7] National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts----second edition. Approved standard M27-A2. NCCLS, Wayne, PA, USA. 2002. [8] Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.[J]. J Clin Microbiol,2001,39(3):954-958. [9] Mcginnis M R. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology.[J]. J Am Acad Dermatol,1983,8(1):1-16. [10] Rossmann S N, Cernoch P L, Davis J R. Dematiaceous fungi are an increasing cause of human disease.[J]. Clin Infect Dis,1996,22(1):73-80. [11] Oztas E, Odemis B, Kekilli M, et al. Systemic Phaeohyphomycosis Caused by Exophiala dermatitidis Resembling Primary Sclerosing Cholangitis.[J]. J Med Microbiol,2009,58(9):1243-1246 [12] Alabaz D, Kibar F, Arikan S, et al. Systemic phaeohyphomycosis due to Exophiala (Wangiella) in an immunocompetent child.[J]. Med Mycol,2009, 47(6):653-657 [13] Chang X, Li R, Yu J, et al. Phaeohyphomycosis of the central nervous system caused by Exophiala dermatitidis in a 3-year-old immunocompetent host.[J]. J Child Neurol,2009,24(3):342-345. [14] Filizzola M J, Martinez F, Rauf S J. Phaeohyphomycosis of the central nervous system in immunocompetent hosts: report of a case and review of the literature.[J]. Int J Infect Dis,2003,7(4):282-286. [15] Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review.[J]. Expert Opin Pharmacother,2009,10(16):2723-2733. [16] Hope W W, Billaud E M, Lestner J, et al. Therapeutic drug monitoring for triazoles.[J]. Curr Opin Infect Dis,2008,21(6):580-586. [17] Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.[J]. Clin Infect Dis,2003,37(5):728-732.